A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy
Abstract
Our overall goal remains to bring epigenetic therapy to have major impact for the management of advanced ovarian cancer (OC). This past year, we continue to make exciting advances in our pre-clinical work and interim results from our leveraged clinical trial is pending now for low dose therapy targeting DNA demethylation paired with immune checkpoint therapy. The results of our two relevant, published studies of mouse models have attracted a great deal of attention, including our study of a OC model in which we have identified that the demethylating agent, 5-aza-cytidine (AZA) potently stimulates tumor immune attraction of T-cells to the tumor microenvironment (PNAS, 2017). For components of this treatment paradigm, (Cell, 2017, PNAS, 2017), during the past year we have broadened the degree of immune pathway signaling involved for OC as described in our report below. Studies of how an inhibitor of G9A, an enzyme mediating transcriptional repression, might can augment the above AZA effects for OC continue as well (Cancer Res, 2018). All of the above findings continue to document how epigenetic therapy can potentially improve immune checkpoint therapy for OC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1100002
Entities
People
- Stephen B. Baylin
Organizations
- Johns Hopkins University